Sep 3, 2026 | Blog
A clinical trial conducted in Africa may recruit African participants, rely on African investigators and address a pressing African health need, yet still route its funding, protocol design, data governance and publication decisions through institutions thousands of...
Aug 27, 2026 | Blog
The global precision medicine project has a foundational problem. The datasets on which it is being built do not represent the species they claim to serve. According to the GWAS Diversity Monitor, populations from the African continent account for approximately 0.16%...
Aug 20, 2026 | Blog
A clinical trial can reach its enrollment target and still produce evidence that is too narrow for the population it is intended to serve. The headline number may look reassuring, but it does not reveal whether the cohort reflects the relevant differences in age, sex,...
Aug 13, 2026 | Blog
A multi-country clinical trial can follow one protocol, test one investigational product, and pursue one scientific question, yet encounter different submission formats, review requirements, amendment procedures, and decision timelines in every participating country. ...
Aug 6, 2026 | Blog
A medicine may complete clinical trials with an acceptable safety profile and still reveal important risks only after thousands, or millions, of people begin using it. Approval is not the end of safety assessment. It is the point at which monitoring must expand from a...
Jul 30, 2026 | Blog
A video consultation can replace a clinic visit. It cannot replace clinical judgment, reliable connectivity, regulatory oversight, or accountable data governance. That distinction is often blurred in discussions about decentralized clinical trials (DCTs). Remote...
